<blockquote><span style="font-size:90%">Quote:<hr/> This is such utter nonsense. Spin works both ways. AF is going to have his spin regardless, and you want the company to have an equal opportunity to publish its own spin. But in both cases the spin is ultimately meaningless. Data on a Phase 3 trial speaks for itself. There is no way around it. You've either got the goods or you don't, and no amount of spin either way is going to change the facts. <br /> <br /> The scientific community (and ultimately the market) is going to see right through the spin, because the data speaks for itself. That's why 99 percent of these biotechs release TLD without a need for a simultaneous explanatory (spin) paper. The data speaks for itself. And BSB is right. The way to defeat AF is by treating him like the nobody he is, and not by building your entire data-release approach around him. There is nothing that will empower him more than what the company is doing right now. <br /> <br /> This whole thing is a sham, and no company with really good data would go about releasing it this way. Only a company that needs to create a false narrative about the data would go about releasing it this way. You know it, I know it, and everybody else knows it. Because data speaks for itself.</span><hr/></blockquote> <br /> <br /> Data never speaks for it's self, data is nothing without context and the whole point of a peer review journal is to have peer review the context applied. You can repeat "the data speaks for itself" all you want, it doesn't make it any more true.